Cargando…
Competing risk analysis of cardiovascular death in patients with primary gallbladder cancer
BACKGROUND: Developments in medical technology are resulting in continuous decreases in the cancer mortality rate of patients with gallbladder cancer, while non‐cancer deaths in cancer patients are becoming more common. The main cause of this is cardiovascular mortality (CVM). The purpose of this st...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939154/ https://www.ncbi.nlm.nih.gov/pubmed/35920057 http://dx.doi.org/10.1002/cam4.5104 |
_version_ | 1784890784405782528 |
---|---|
author | Chen, Chong Xu, Fengshuo Yuan, Shiqi Zhao, Xuenuo Qiao, Mengmeng Han, Didi Lyu, Jun |
author_facet | Chen, Chong Xu, Fengshuo Yuan, Shiqi Zhao, Xuenuo Qiao, Mengmeng Han, Didi Lyu, Jun |
author_sort | Chen, Chong |
collection | PubMed |
description | BACKGROUND: Developments in medical technology are resulting in continuous decreases in the cancer mortality rate of patients with gallbladder cancer, while non‐cancer deaths in cancer patients are becoming more common. The main cause of this is cardiovascular mortality (CVM). The purpose of this study was to determine the CVM risk in patients with primary gallbladder cancer (PGC). METHODS: We extracted information on patients in the SEER database who were diagnosed with PGC from 2004 to 2015, compared CVM in patients with PGC with the general United States population, and calculated standardized mortality rates (SMRs) and the absolute excess risk. A competing risks model was used to identify and analyze the independent risk factors for cardiovascular death in patients with PGC. RESULTS: This study included 5925 patients, 247 of whom died from cardiovascular disease. The SMR of cardiovascular death in patients with PGC was 15.84 (95% confidence interval: 15.83–15.85), and the SMR was slightly lower in male than female patients. The competing risks analysis indicated that age, marital status, cancer cell differentiation, chemotherapy status, and year of diagnosis were risk factors for cardiovascular death in patients with PGC. CONCLUSIONS: The CVM risk is considerably higher in patients with PGC than in the general population. It is therefore very necessary to apply cardioprotective interventions to patients with PGC. |
format | Online Article Text |
id | pubmed-9939154 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-99391542023-02-20 Competing risk analysis of cardiovascular death in patients with primary gallbladder cancer Chen, Chong Xu, Fengshuo Yuan, Shiqi Zhao, Xuenuo Qiao, Mengmeng Han, Didi Lyu, Jun Cancer Med REVIEWS BACKGROUND: Developments in medical technology are resulting in continuous decreases in the cancer mortality rate of patients with gallbladder cancer, while non‐cancer deaths in cancer patients are becoming more common. The main cause of this is cardiovascular mortality (CVM). The purpose of this study was to determine the CVM risk in patients with primary gallbladder cancer (PGC). METHODS: We extracted information on patients in the SEER database who were diagnosed with PGC from 2004 to 2015, compared CVM in patients with PGC with the general United States population, and calculated standardized mortality rates (SMRs) and the absolute excess risk. A competing risks model was used to identify and analyze the independent risk factors for cardiovascular death in patients with PGC. RESULTS: This study included 5925 patients, 247 of whom died from cardiovascular disease. The SMR of cardiovascular death in patients with PGC was 15.84 (95% confidence interval: 15.83–15.85), and the SMR was slightly lower in male than female patients. The competing risks analysis indicated that age, marital status, cancer cell differentiation, chemotherapy status, and year of diagnosis were risk factors for cardiovascular death in patients with PGC. CONCLUSIONS: The CVM risk is considerably higher in patients with PGC than in the general population. It is therefore very necessary to apply cardioprotective interventions to patients with PGC. John Wiley and Sons Inc. 2022-08-03 /pmc/articles/PMC9939154/ /pubmed/35920057 http://dx.doi.org/10.1002/cam4.5104 Text en © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | REVIEWS Chen, Chong Xu, Fengshuo Yuan, Shiqi Zhao, Xuenuo Qiao, Mengmeng Han, Didi Lyu, Jun Competing risk analysis of cardiovascular death in patients with primary gallbladder cancer |
title | Competing risk analysis of cardiovascular death in patients with primary gallbladder cancer |
title_full | Competing risk analysis of cardiovascular death in patients with primary gallbladder cancer |
title_fullStr | Competing risk analysis of cardiovascular death in patients with primary gallbladder cancer |
title_full_unstemmed | Competing risk analysis of cardiovascular death in patients with primary gallbladder cancer |
title_short | Competing risk analysis of cardiovascular death in patients with primary gallbladder cancer |
title_sort | competing risk analysis of cardiovascular death in patients with primary gallbladder cancer |
topic | REVIEWS |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939154/ https://www.ncbi.nlm.nih.gov/pubmed/35920057 http://dx.doi.org/10.1002/cam4.5104 |
work_keys_str_mv | AT chenchong competingriskanalysisofcardiovasculardeathinpatientswithprimarygallbladdercancer AT xufengshuo competingriskanalysisofcardiovasculardeathinpatientswithprimarygallbladdercancer AT yuanshiqi competingriskanalysisofcardiovasculardeathinpatientswithprimarygallbladdercancer AT zhaoxuenuo competingriskanalysisofcardiovasculardeathinpatientswithprimarygallbladdercancer AT qiaomengmeng competingriskanalysisofcardiovasculardeathinpatientswithprimarygallbladdercancer AT handidi competingriskanalysisofcardiovasculardeathinpatientswithprimarygallbladdercancer AT lyujun competingriskanalysisofcardiovasculardeathinpatientswithprimarygallbladdercancer |